Biogen BIIB MS Product Revenues — Total Revenue

Other product segments

Similar metrics at other companies

OMCLProduct revenues — Total revenues

$174.8M+20.4%

ORGOProduct — Revenue

$36.25M-58.2%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

LLYNet product revenue — Revenue

$18.45B+59.1%

BMRNNet product revenues — Total revenues

$760.08M+3.5%

GILDProduct sales — Total revenues

$6.95B+5.0%

Questions, answered.

What is Biogen's MS product revenues — total revenue?

Biogen (BIIB) reported MS product revenues — total revenue of $957.5M in Q1 2026.

How has Biogen's MS product revenues — total revenue changed year-over-year?

Biogen's MS product revenues — total revenue increased by 0.5% year-over-year, from $953M to $957.5M.

What is the long-term trend for Biogen's MS product revenues — total revenue?

Over 4 years (2021 to 2025), Biogen's MS product revenues — total revenue has grown at a -9.8% compound annual growth rate (CAGR), from $6.1B to $4.04B.

What does MS product revenues — total revenue mean?

This metric represents the aggregate gross revenue generated from the sale of the company's portfolio of multiple sclerosis (MS) therapeutic products. It encompasses income derived from established and novel MS treatments, reflecting the company's core market position in the neurology space. This revenue stream is a primary indicator of the commercial performance and market penetration of the company's flagship disease-modifying therapies.